Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab

Atopic Dermatitis

Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials

Adv Ther

Ständer S, Yosipovitch G, Simpson EL, Kim BS, Kabashima K, Thaçi D, Metz M, Chen Z, Hagen S, Bastian M

doi: 10.1007/s12325-025-03124-8

Atopic Dermatitis

Switching from dupilumab to tralokinumab or Janus kinase inhibitors in cases of ocular and/or facial adverse events in patients with atopic dermatitis: a multicenter retrospective study

J Allergy Clin Immunol Pract

Beyrouti A, Deuze J, Fontas E, Foureau A, Barbarot S, Aubert H, Bernier C, Le Moigne M, Passeron T, Boukari F, Garnier M, Jachiet M, Tetart F, Seneschal J, Toussaint C, Mahé E, Leleu C, Regnault MM, Pasteur J, Nosbaum A, Badaoui A, Fougerousse AC, Pralong P, Viguier M, Droitcourt C, Abasq C, Mallet S, Raison-Peyron N, Staumont-Sallé D, Hubiche T, FRench Atopic DErmatitis Network (FRADEN) from the Groupe de Recherche sur l’Eczéma Atopique (GREAT) Research Group

doi: 10.1016/j.jaip.2024.12.001

Atopic Dermatitis

The real-world, long-term risk of infections associated with dupilumab in atopic dermatitis: A global cohort study

J Eur Acad Dermatol Venereol

Kridin K, Abdelghaffar M, Bieber K, Thaci D, Ludwig RJ

doi: 10.1111/jdv.20724

Atopic Dermatitis

One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis

Adv Ther

Calzavara-Pinton P, Chu CY, Lapeere H, Rossi M, Ferrucci SM, Chung WH, Fougerousse AC, Fomina DS, Holzer G, Čelakovská J, Al-Ahmad M, Tzellos T, Wu J, Ardeleanu M, Bosman K

doi: 10.1007/s12325-024-03049-8

Atopic Dermatitis

Risk of Developing Pediatric Uveitis Among Patients With Early-Onset Atopic Dermatitis

JAMA Ophthalmol

Chu YY, Sung CH, Lin YS, Ho CH, Chen YC, Lee WA, Kuo SC

doi: 10.1001/jamaophthalmol.2025.0366

Atopic DermatitisPsoriasis

Happiness across the borders-A cross-sectional study among patients with psoriasis and atopic dermatitis in Europe

J Eur Acad Dermatol Venereol

Ziehfreund S, Wecker H, Mittag S, Weis J, Tizek L, Verkhoturova V, Legat FJ, Weger W, Großschädl K, Cerpes U, Sadoghi B, Riegler M, Balato A, Di Brizzi EV, Buononato D, Babino G, Calzavara-Pinton P, Rossi MT, Rovaris S, Dimech A, Boffa MJ, Chernyshov P, Svyatenko T, Kolodzinska L, Sikora M, Torres T, Manolache L, Scala E, Biedermann T, Zink A

doi: 10.1111/jdv.20288

Atopic Dermatitis

A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register

Br J Dermatol

Alexander H, Malek R, Prieto-Merino D, Gribaleva E, Baden M, Beattie P, Brown S, Burton T, Cameron S, Coker B, Cork MJ, Hearn R, Ingram JR, Irvine AD, Johnston GA, Lambert A, Lunt M, Man I, Newell L, Ogg G, Patel P, Wan M, Warren RB, Woolf R, Yiu ZZN, Reynolds N, Ardern-Jones MR, Flohr C, UK-Irish A-STAR Study Group

doi: 10.1093/bjd/ljae287

Atopic Dermatitis

The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: results from a placebo-controlled, phase 3 study

J Am Acad Dermatol

Paller AS, Silverberg JI, Simpson EL, Cork MJ, Arkwright PD, Chen Z, Bansal A, Prescilla R, Wang Z, Marco AR

doi: 10.1016/j.jaad.2024.09.039

Allergic Diseases

Allergic contact dermatitis in adults with and without atopic dermatitis: Evaluation of the Spanish Contact Dermatitis Registry (REIDAC)

Contact Dermatitis

Chicharro P, Munera-Campos M, Zaragoza-Ninet V, Giménez-Arnau A, González-Pérez R, Miquel-Miquel FJ, Córdoba-Guijarro S, Sanz-Sánchez T, Ruiz-González I, Silvestre-Salvador JF, Serra-Baldrich E, Borrego L, Pastor-Nieto MA, Ortiz de Frutos FJ, Mercader-García P, Heras-Mendaza F, Fernández-Redondo V, Rodríguez-Serna M, Hervella-García M, Carrascosa JM, Gallego-Descalzo MA, García-Doval I, Sánchez-Pérez J

doi: 10.1111/cod.14672

Related content

Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials

Switching from dupilumab to tralokinumab or Janus kinase inhibitors in cases of ocular and/or facial adverse events in patients with atopic dermatitis: a multicenter retrospective study

The real-world, long-term risk of infections associated with dupilumab in atopic dermatitis: A global cohort study

One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis

Risk of Developing Pediatric Uveitis Among Patients With Early-Onset Atopic Dermatitis

Happiness across the borders-A cross-sectional study among patients with psoriasis and atopic dermatitis in Europe

A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register

The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: results from a placebo-controlled, phase 3 study

Allergic contact dermatitis in adults with and without atopic dermatitis: Evaluation of the Spanish Contact Dermatitis Registry (REIDAC)